Jing Xiao

Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis

M. D. de Bruin‐Weller, T. Nakahara, A. Shabbir, 2022, American Journal of Clinical Dermatology.

Dupilumab in Adults With Moderate to Severe Atopic Dermatitis: A 5-Year Open-Label Extension Study.

Jing Xiao, Lisa A. Beck, A. Dubost-Brama, 2024, JAMA dermatology.